The effects of polyunsaturated fatty acids and their metabolites on osteoclastogenesis in vitro

Prostaglandins and Other Lipid Mediators

Volumn 92, Issue 1-4, 2010, Pages 85-90

  Yuan, Jizhong ^a   Akiyama, Masako ^a   Nakahama, Ken ichi ^a   Sato, Takahiro ^a   Uematsu, Hiroshi ^a   Morita, Ikuo ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase; Lipoxygenase; Osteoclastogenesis; Polyunsaturated fatty acid; Prostaglandin

Indexed keywords

ARACHIDONIC ACID; DIHOMO GAMMA LINOLENIC ACID; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INDOMETACIN; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; MESSENGER RNA; NORDIHYDROGUAIARETIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; RESOLVIN D1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; IN VITRO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS;

ANIMALS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CYCLOOXYGENASE INHIBITORS; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS, UNSATURATED; GENE EXPRESSION REGULATION; LIPOXYGENASE; MALE; MICE; OSTEOCLASTS; PROSTAGLANDINS E;

EID: 77952106074     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2010.04.001     Document Type: Article

References (34)

1. Takayanagi H., Kim S., Koga T., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3 (2002) 889-901
2. Gao Q., Xu M., Alander C.B., Choudhary S., Pilbeam C.C., and Raisz L.G. Effects of prostaglandin E-2 on bone in mice in vivo. Prostaglandin Other Lipid Mediat 89 (2009) 20-25
3. Collins D.A., and Chambers T.J. Prostaglandin-E2 promotes osteoclast formation in murine hematopoietic cultures through an action on hematopoietic-cells. J Bone Miner Res 7 (1992) 555-561
4. Kaji H., Sugimoto T., Kanatani M., Fukase M., Kumegawa M., and Chihara K. Prostaglandin E(2) stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase. J Bone Miner Res 11 (1996) 62-71
5. Krieger N.S., Parker W.R., Alexander K.M., and Bushinsky D.A. Prostaglandins regulate acid-induced cell-mediated bone resorption. Am J Physiol Renal 279 (2000) F1077-F1082
6. Suzawa T., Miyaura C., Inada M., et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 141 (2000) 1554-1559
7. Kruger M.C., Coetzer H., de Winter R., Gericke G., and van Papendorp D.H. Calcium gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. Aging Clin Exp Res 10 (1998) 385-394
8. Fujita D., Yamashita N., Iita S., Amano H., Yamada S., and Sakamoto K. Prostaglandin E-2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. Prostaglandins Leukot Essent Fatty Acids 68 (2003) 351-358
9. Kobayashi Y., Mizoguchi T., Take I., Kurihara S., Udagawa N., and Takahashi N. Prostaglandin E-2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. J Biol Chem 280 (2005) 11395-11403
10. Chappard D., Alexandre C., and Riffat G. Histochemical identification of osteoclasts. Review of current methods and reappraisal of a simple procedure for routine diagnosis on undecalcified human iliac bone biopsies. Basic Appl Histochem 27 (1983) 75-85
11. Kruger M.C., Coetzer H., de Winter R., Gericke G., and van Papendorp D.H. Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. Aging (Milano) 10 (1998) 385-394
12. Sakaguchi K., Morita I., and Murota S. Eicosapentaenoic acid inhibits bone loss due to ovariectomy in rats. Prostaglandins Leukot Essent Fatty Acids 50 (1994) 81-84
13. Fernandes G., Lawrence R., and Sun D. Protective role of n-3 lipids and soy protein in osteoporosis. Prostaglandins Leukot Essent Fatty Acids 68 (2003) 361-372
14. Sun L., Tamaki H., Ishimaru T., et al. Inhibition of osteoporosis due to restricted food intake by the fish oils DHA and EPA and perilla oil in the rat. Biosci Biotechnol Biochem 68 (2004) 2613-2615
15. Yasuda H., Shima N., Nakagawa N., et al. A novel molecular mechanism modulating osteoclast differentiation and function. Bone 25 (1999) 109-113
16. Bezerra M.C., Carvalho J.F., Prokopowitsch A.S., and Pereira R.M. RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz J Med Biol Res 38 (2005) 161-170
17. Wani M.R., Fuller K., Kim N.S., Choi Y., and Chambers T. Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 140 (1999) 1927-1935
18. Kobayashi Y., Mizoguchi T., Take I., Kurihara S., Udagawa N., and Takahashi N. Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. J Biol Chem 280 (2005) 11395-11403
19. Jiang J., Lv H.S., Lin J.H., Jiang D.F., and Chen Z.K. LTB4 can directly stimulate human osteoclast formation from PBMC independent of RANKL. Artif Cells Blood Substit Immobil Biotechnol 33 (2005) 391-403
20. Kronke G., Uderhardt S., Katzenbeisser J., and Schett G. The 12/15-lipoxygenase pathway promotes osteoclast development and differentiation. Autoimmunity 42 (2009) 383-385
21. Rahman M.M., Bhattacharya A., and Fernandes G. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid. J Cell Physiol 214 (2008) 201-209
22. Tsuboi K., Sugimoto Y., and Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 68-69 (2002) 535-556
23. Kobayashi Y., Take I., Yamashita T., et al. Prostaglandin E2 receptors EP2 and EP4 are down-regulated during differentiation of mouse osteoclasts from their precursors. J Biol Chem 280 (2005) 24035-24042
24. Tsujisawa T., Inoue H., and Nishihara T. SC-19220 antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL. J Bone Miner Res 20 (2005) 15-22
25. Mano M., Arakawa T., Mano H., et al. Prostaglandin E2 directly inhibits bone-resorbing activity of isolated mature osteoclasts mainly through the EP4 receptor. Calcif Tissue Int 67 (2000) 85-92
26. Serhan C.N. Novel omega-3-derived local mediators in anti-inflammation and resolution. Pharmacol Ther 105 (2005) 7-21
27. Serhan C.N., and Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol 153 Suppl. 1 (2008) S200-S215
28. Serhan C.N., Chiang N., and Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8 (2008) 349-361
29. Duffield J.S., Hong S., Vaidya V.S., et al. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol 177 (2006) 5902-5911
30. Tian H., Lu Y., Sherwood A.M., Hongqian D., and Hong S. Resolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes: biosynthesis and mechanisms of anti-inflammatory actions. Invest Ophthalmol Vis Sci 50 (2009) 3613-3620
31. Kukita T., Wada N., Kukita A., et al. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med 200 (2004) 941-946
32. Yagi M., Miyamoto T., Sawatani Y., et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202 (2005) 345-351
33. Kishida E., Tajiri M., and Masuzawa Y. Docosahexaenoic acid enrichment can reduce L929 cell necrosis induced by tumor necrosis factor. Biochim Biophys Acta 1761 (2006) 454-462
34. Mori T.A., Bao D.Q., Burke V., Puddey I.B., and Beilin L.J. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 34 (1999) 253-260